Latest News & Features
Careers
Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs. 16 April 2024
Big Pharma
Judges determine six claims of Novarad’s AR patent to be unpatentable but uphold a further claim | Decision follows unsuccessful challenge by Medivis to another Novarad patent in March. 16 April 2024
Biotechnology
A US District Court has granted a motion to stay the company’s lawsuit against Pfizer and BioNTech | Decision pauses proceedings until two inter partes review proceedings are resolved. 16 April 2024
Big Pharma
Endo and its subsidiary have challenged the FDA's approval of an application by BPI Labs and Belcher Pharmaceuticals | Dispute argues the FDA undermined regulatory frameworks and patent protection. 11 April 2024
Big Pharma
Diabetes drug is known for its off-label use as a weight-loss aid | Judge censures pharma giant for using state law instead of federal law in complaint | Development follows a wave of litigation involving Mounjaro. 11 April 2024
Biotechnology
Delaware district court more convinced by Arbutus on claim construction points | Canadian biotech “pleased” with outcome in latest round of dispute over lipid nanoparticles delivery system. 9 April 2024
Big Pharma
Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion |
Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan. 9 April 2024
Medtech
The Federal Circuit upholds a ruling in favour of Microsoft against an Orlando tech company | Dispute concerned 3D medical imaging technology | Court affirms PTAB’s decision to invalidate most of the patent. 4 April 2024
Big Pharma
Senior pharma attorney and LSPN Boston speaker delves into emerging tech and patent law, the importance of communication and awareness, and the challenge of enablement | Advice on effective management of IP portfolios in the life sciences sector. 4 April 2024
Generics
Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent. 2 April 2024